logo

TGTX

Tg TherapeuticsยทNASDAQ
--
--(--)
--
--(--)

TGTX Profile

Tg Therapeutics, Inc.

A biopharmaceutical company that develops therapeutics for diseases caused by protien or gene dysfunction

Pharmaceutical
--
05/30/2013
NASDAQ Stock Exchange
338
12-31
Common stock
3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560
--
TG Therapeutics, Inc., was incorporated in Delaware in 1993. The company is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development and commercialization of new therapies for B cell-mediated diseases. Its product BRIUMVI (ublituximab-xiiy) has received regulatory approval in the US, EU and UK for the treatment of adult patients with relapsing multiple sclerosis.